BACKGROUND: Some patients with nonischemic left ventricular (LV) systolic failure recover to have normal LV systolic function. However, few studies on the rates of recovery and recurrence have been reported, and no definitive indicators that can predict the recurrence of LV dysfunction in recovered idiopathic dilated cardiomyopathy (IDCMP) patients have been determined. It was hypothesized that patients who recovered from nonischemic LV dysfunction have a substantial risk for recurrent heart failure. METHODS: Forty-two patients (32 men) with IDCMP (mean [+/- SD] age 56.9+/-8.7 years) who recovered from systolic heart failure (LV ejection fraction [LVEF] of 26.5+/-6.9% at initial presentation) to a near-normal state (LVEF of 40% or greater, and a 10% increase or greater in absolute value) were monitored for recurrence of LV systolic dysfunction. Patients with significant coronary artery disease were excluded. Patients were monitored for 41.0+/-26.3 months after recovery (LVEF 53.4+/-7.6%) from LV dysfunction. RESULTS: LV systolic dysfunction reappeared (LVEF 27.5+/-8.1%) during the follow-up period in eight of 42 patients (19.0%). No significant difference between the groups with or without recurrent heart failure was observed in the baseline clinical and echocardiographic characteristics. However, more patients in the recurred IDCMP group than those in the group that maintained the recovery state had discontinued antiheart failure medication (62.5% versus 5.9%, P<0.05). CONCLUSIONS: LV dysfunction recurs in some patients with reversible IDCMP. The recurrence was significantly correlated with the discontinuation of antiheart failure drugs. The results suggest that continuous medical therapy may be mandatory in patients who recover from LV systolic dysfunction.
BACKGROUND: Some patients with nonischemic left ventricular (LV) systolic failure recover to have normal LV systolic function. However, few studies on the rates of recovery and recurrence have been reported, and no definitive indicators that can predict the recurrence of LV dysfunction in recovered idiopathic dilated cardiomyopathy (IDCMP) patients have been determined. It was hypothesized that patients who recovered from nonischemic LV dysfunction have a substantial risk for recurrent heart failure. METHODS: Forty-two patients (32 men) with IDCMP (mean [+/- SD] age 56.9+/-8.7 years) who recovered from systolic heart failure (LV ejection fraction [LVEF] of 26.5+/-6.9% at initial presentation) to a near-normal state (LVEF of 40% or greater, and a 10% increase or greater in absolute value) were monitored for recurrence of LV systolic dysfunction. Patients with significant coronary artery disease were excluded. Patients were monitored for 41.0+/-26.3 months after recovery (LVEF 53.4+/-7.6%) from LV dysfunction. RESULTS:LV systolic dysfunction reappeared (LVEF 27.5+/-8.1%) during the follow-up period in eight of 42 patients (19.0%). No significant difference between the groups with or without recurrent heart failure was observed in the baseline clinical and echocardiographic characteristics. However, more patients in the recurred IDCMP group than those in the group that maintained the recovery state had discontinued antiheart failure medication (62.5% versus 5.9%, P<0.05). CONCLUSIONS:LV dysfunction recurs in some patients with reversible IDCMP. The recurrence was significantly correlated with the discontinuation of antiheart failure drugs. The results suggest that continuous medical therapy may be mandatory in patients who recover from LV systolic dysfunction.
Authors: M Takahashi; H Tsutsui; S Kinugawa; K Igarashi-Saito; S Yamamoto; M Yamamoto; H Tagawa; K Imanaka-Yoshida; K Egashira; A Takeshita Journal: J Mol Cell Cardiol Date: 1998-05 Impact factor: 5.000
Authors: Sandra Amorim; João Rodrigues; Manuel Campelo; Brenda Moura; Elisabete Martins; Filipe Macedo; J Silva-Cardoso; M Júlia Maciel Journal: Int J Cardiovasc Imaging Date: 2016-12-24 Impact factor: 2.357
Authors: Anupam Basuray; Benjamin French; Bonnie Ky; Esther Vorovich; Caroline Olt; Nancy K Sweitzer; Thomas P Cappola; James C Fang Journal: Circulation Date: 2014-05-05 Impact factor: 29.690
Authors: Luigi Adamo; Andrew Perry; Eric Novak; Majesh Makan; Brian R Lindman; Douglas L Mann Journal: Circ Heart Fail Date: 2017-06 Impact factor: 8.790
Authors: Marco Merlo; Marco Masè; Andrew Perry; Eluisa La Franca; Elena Deych; Laura Ajello; Diego Bellavia; Andrea Boscutti; Marco Gobbo; Giuseppe Romano; Davide Stolfo; John Gorcsan; Francesco Clemenza; Gianfranco Sinagra; Luigi Adamo Journal: Heart Date: 2021-09-07 Impact factor: 5.994
Authors: Wilson Nadruz; Erin West; Mário Santos; Hicham Skali; John D Groarke; Daniel E Forman; Amil M Shah Journal: Circ Heart Fail Date: 2016-04 Impact factor: 8.790
Authors: Andrew C Kao; Steven W Krause; Rajiv Handa; Darshak Karia; Guillermo Reyes; Nicole R Bianco; Steven J Szymkiewicz Journal: BMC Cardiovasc Disord Date: 2012-12-12 Impact factor: 2.298
Authors: Brian P Halliday; Rebecca Wassall; Amrit S Lota; Zohya Khalique; John Gregson; Simon Newsome; Robert Jackson; Tsveta Rahneva; Rick Wage; Gillian Smith; Lucia Venneri; Upasana Tayal; Dominique Auger; William Midwinter; Nicola Whiffin; Ronak Rajani; Jason N Dungu; Antonis Pantazis; Stuart A Cook; James S Ware; A John Baksi; Dudley J Pennell; Stuart D Rosen; Martin R Cowie; John G F Cleland; Sanjay K Prasad Journal: Lancet Date: 2018-11-11 Impact factor: 79.321